Dave Singh, MD, reflects on 2027 GOLD report refinements, from mucus plugs and early COPD to biologics awaiting regulatory approval.
News|Articles|April 2, 2025
Psychiatry Month in Review: March 2025
Author(s)Chelsie Derman
This month in review spotlights phase 2 and 3 trials and discovered associations in the psychiatry field.
Advertisement
Advertisement
March brought important developments in mental health research. A meta-analysis confirmed that GLP-1 receptor agonists do not increase the risk of suicide or self-harm, easing concerns around their safety in managing diabetes and obesity. Meanwhile, a study on daily discrimination highlighted its strong link to depression and anxiety, with marginalized groups facing greater risks. Both studies underscore the need for ongoing research and more targeted care in mental health treatment.
Related to this article
Retrospective data show semaglutide 2.4 mg was linked to lower liver enzymes, weight, and HbA1c in MASH, including vs resmetirom in a real-world cohort.
Francesca Polverino, MD, PhD, explains how oxidized and reduced IL-33 drive mucus dysfunction and inflammation in COPD, and why mucus plugs matter.
Phase 2 ENHANCE and ENRICH data show BRII-179 plus elebsiran and peginterferon increased HBsAg loss in chronic HBV, with priming halving peginterferon use.
Pooled phase 2 data show fazirsiran 200 mg cut intrahepatic Z-AAT by about 90% vs placebo in AATD liver disease, with stable lung function through the OLE.
Once-monthly efimosfermin alfa reduced liver stiffness, ELF, and PRO-C3 through 52 weeks in MASH with F2–F4 fibrosis, including compensated cirrhosis.
Alvar Agustí, MD, previews key 2027 GOLD report changes, from initial COPD treatment and new biologic data to a GOLD Science Committee call to action.
In a phase 2 decentralized study, once-daily trientine tetrahydrochloride improved convenience and adherence in Wilson disease; 80% preferred it.
Advertisement
Advertisement